Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Itraconazole and multidrug resistance: possible effects on remission rate and disease-free survival in acute leukemia.

Vreugdenhil G, Raemaekers JM, van Dijke BJ, de Pauw BE.

Ann Hematol. 1993 Sep;67(3):107-9.

PMID:
8396989
2.

Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy.

Mattiuzzi GN, Kantarjian H, O'Brien S, Kontoyiannis DP, Giles F, Zhou X, Lim J, Bekele BN, Faderl S, Cortes J, Pierce S, Leitz GJ, Raad I, Estey E.

Cancer. 2004 Feb 1;100(3):568-73.

3.

Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study.

List AF, Kopecky KJ, Willman CL, Head DR, Persons DL, Slovak ML, Dorr R, Karanes C, Hynes HE, Doroshow JH, Shurafa M, Appelbaum FR.

Blood. 2001 Dec 1;98(12):3212-20.

4.

Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.

Creutzig U, Ritter J, Zimmermann M, Reinhardt D, Hermann J, Berthold F, Henze G, Jürgens H, Kabisch H, Havers W, Reiter A, Kluba U, Niggli F, Gadner H.

J Clin Oncol. 2001 May 15;19(10):2705-13.

PMID:
11352963
5.

Prophylaxis of fungal infections with itraconazole during remission-induction therapy.

Prentice AG, Bradford GR.

Mycoses. 1989;32 Suppl 1:96-102.

PMID:
2561190
6.
7.

Role of daunorubicin in the induction therapy for adult acute myeloid leukemia.

Usui N, Dobashi N, Kobayashi T, Yano S, Maki N, Asai O, Saito T, Yamaguchi Y, Watanabe H, Kato A, Ogihara A, Katori M, Nagamine M, Takei Y, Yamazaki H, Funakoshi S, Tajima N, Ogawa M, Kuraishi Y.

J Clin Oncol. 1998 Jun;16(6):2086-92.

PMID:
9626208
8.
9.

A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study.

Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP, Bickers JN, Hynes HE, Welborn JL, Simon SR, Grever M.

Blood. 1996 Oct 15;88(8):2841-51.

10.

[The role of daunorubicin in induction therapy for adult acute myeloid leukemia].

Usui N, Dobashi N, Asai O, Yano S, Kato A, Osawa H, Uno S, Katori M, Nagamine M, Yahagi Y, Yamaguchi Y, Saito T, Kasama K, Takei Y, Ogihara A, Yamazaki H, Kobayashi T, Tajima N, Ogawa M, Kuraishi Y.

Gan To Kagaku Ryoho. 2000 Jul;27(8):1152-9. Japanese.

PMID:
10945010
11.

Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies.

Tricot G, Joosten E, Boogaerts MA, Vande Pitte J, Cauwenbergh G.

Rev Infect Dis. 1987 Jan-Feb;9 Suppl 1:S94-9.

PMID:
3027853
12.
13.

Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors for outcomes of adults transplanted in first complete remission.

Fouillard L, Labopin M, Gratwohl A, Gluckman E, Frassoni F, Beelen DW, Willemze R, Montserrat E, Blaise D, Atienza AI, Sierra J, Santos M, Gorin NC, Rocha V; Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Haematologica. 2008 Jun;93(6):834-41. doi: 10.3324/haematol.11277. Epub 2008 May 10.

14.

The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: a Japanese multicenter randomized, controlled study.

Ito Y, Ohyashiki K, Yoshida I, Takeuchi M, Aoyama Y, Mugitani A, Matsuura Y, Wakita H, Matsuda M, Sakamoto E, Kiguchi T, Urabe A, Tamura K, Kanamaru A, Masaoka T.

Int J Hematol. 2007 Feb;85(2):121-7.

PMID:
17321989
15.

A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM).

Witz F, Sadoun A, Perrin MC, Berthou C, Brière J, Cahn JY, Lioure B, Witz B, François S, Desablens B, Pignon B, Le Prisé PY, Audhuy B, Caillot D, Casassus P, Delain M, Christian B, Tellier Z, Polin V, Hurteloup P, Harousseau JL.

Blood. 1998 Apr 15;91(8):2722-30.

16.

A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111.

Larson RA, Dodge RK, Linker CA, Stone RM, Powell BL, Lee EJ, Schulman P, Davey FR, Frankel SR, Bloomfield CD, George SL, Schiffer CA.

Blood. 1998 Sep 1;92(5):1556-64.

17.
18.

Reversal of daunorubicin resistance in P388/ADR cells by itraconazole.

Gupta S, Kim J, Gollapudi S.

J Clin Invest. 1991 Apr;87(4):1467-9.

19.

[Results of the treatment of acute leukemia in adolescents].

Ruiz-Argüelles GJ, Apreza-Molina MG.

Rev Invest Clin. 1997 Jul-Aug;49(4):271-5. Spanish.

PMID:
9707991
20.

Expression of the lung resistance protein predicts poor outcome in de novo acute myeloid leukemia.

Filipits M, Pohl G, Stranzl T, Suchomel RW, Scheper RJ, Jäger U, Geissler K, Lechner K, Pirker R.

Blood. 1998 Mar 1;91(5):1508-13.

Items per page

Supplemental Content

Write to the Help Desk